NCT01841359View on ClinicalTrials.gov

Pramlintide (Symlin) for the Treatment of Hypoglycemia Following Gastric Bypass Surgery

PHASE4CompletedINTERVENTIONAL

Enrollment

22

Participants

Timeline

Start Date

February 2, 2010

Primary Completion Date

July 31, 2016

Study Completion Date

February 8, 2022

Conditions

HypoglycemiaEvidence of Previous Gastric Surgery

Interventions

DRUG

Pramlintide

See description above (arm description).

Trial Locations (1)

02215

Joslin Diabetes Center, Boston

Sponsors

Collaborators (1)

Bristol-Myers Squibb

All Listed Sponsors

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Joslin Diabetes Center

OTHER

NCT01841359 - Pramlintide (Symlin) for the Treatment of Hypoglycemia Following Gastric Bypass Surgery | Biotech Hunter | Biotech Hunter